Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 11/20 | 0.67 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | SLC12A5 | Q9H2X9 | 2/20 | 0.31 |
| ▸ | GCK | P35557 | 1/20 | 0.31 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.30 |
| ▸ | BRS3 | P32247 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | USP19 | O94966 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1916323 | 1.00 | FFAR2 (0.67) | FFAR2CNR2SLC12A5GCKGSTO1 | |
| SCHEMBL1917141 | 0.98 | FFAR2 (0.67) | FFAR2CNR2SLC12A5GCKGSTO1 | |
| SCHEMBL1917136 | 0.98 | FFAR2 (0.67) | FFAR2CNR2SLC12A5GCKGSTO1 | |
| SCHEMBL1917149 | 0.94 | FFAR2 (0.75) | FFAR2CNR2SLC12A5USP19 | |
| SCHEMBL16498011 | 0.94 | FFAR2 (0.73) | FFAR2CNR2SLC12A5USP19 | |
| SCHEMBL16498009 | 0.94 | FFAR2 (0.73) | FFAR2CNR2SLC12A5USP19 | |
| SCHEMBL1916204 | 0.94 | FFAR2 (0.75) | FFAR2CNR2SLC12A5USP19 | |
| SCHEMBL1915693 | 0.94 | FFAR2 (0.66) | FFAR2CNR2SLC12A5 | |
| SCHEMBL2402532 | 0.94 | FFAR2 (0.66) | FFAR2CNR2SLC12A5 | |
| SCHEMBL1916342 | 0.93 | FFAR2 (0.65) | FFAR2CNR2SLC12A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | FFAR2 295/4885CNR2 822/4885SLC12A5 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.